SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): October 2, 2018
Pain Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(I.R.S. Employer Identification Number)|
|7801 N Capital of Texas Highway, Suite 260, Austin, TX 78731|
|(Address of Principal Executive Offices) (Zip Code)|
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
|Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:|
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01. Other Events.
On October 2, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Pain Therapeutics, Inc.|
|Date: October 2, 2018||By:||/s/ Remi Barbier|
|Chairman of the Board of Directors,|
President and Chief Executive Officer
Pain Therapeutics Announces Investor Call to Provide Strategic Update
Call to be Held on Thursday, October 4th, 10:00 AM Eastern Time
AUSTIN, Texas, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline. The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time.
The audio presentation will be available via teleconference, which can be accessed by dialing (877) 407-4018 or (201) 689-8471 for international callers. A toll-free replay will be available at (844) 512-2921, or (412) 317-6671 for international callers, using the conference ID code: 13683822
The Company’s presentation will be available live via webcast and conference call. To listen to the webcast and view the accompanying slide presentation, please go to the Company’s website at http://www.paintrials.com/ and click on the webcast icon at least 15 minutes before the presentation is to begin to register. If you are unable to listen to the live webcast, please access http://www.paintrials.com/ at any time within seven days to listen to a replay of the webcast.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The Company believes its research program in Alzheimer’s disease has game-changing characteristics. Its lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action to treat Alzheimer’s disease. The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, and benefits from several peer-reviewed research grant awards from the National Institutes of Health (NIH).
The Company is also developing a blood test, called PTI-125DX, to detect Alzheimer’s disease, possibly years before symptoms appear. An early diagnosis of Alzheimer's could allow treatment to start sooner, optimize treatment options for each individual and improve chances to slow or halt the disease.
Last, the Company also has an NDA-stage drug asset, REMOXY, for severe chronic pain, which is currently held up at the U.S. Food and Drug Administration (FDA). The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the potential benefits of the Company’s program in Alzheimer’s disease. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to our financial and operational ability to carry out development activities around Alzheimer’s disease. For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.
For More Information Contact:
Pain Therapeutics, Inc.